Emcure Crosses $1 Billion Revenue Milestone in FY26; PAT Jumps 41%

Emcure Pharmaceuticals reported a strong financial performance for FY26, with revenue from operations rising 16.6% year-on-year to ₹9,204 crore, crossing the $1 billion milestone.

Adjusted profit after tax (PAT) surged 40.9% YoY to ₹1,008 crore, while reported PAT stood at ₹941 crore, up 33.1%. EBITDA grew 21.8% to ₹1,789 crore, with margins at 19.4%.

The company’s international business led growth, rising 22.2% YoY to ₹5,177 crore, while domestic sales grew 10% to ₹4,027 crore.

Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “In FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over US$1 billion in revenue and 16.6% growth. International markets demonstrated robust momentum while our domestic business recorded steady growth. We delivered ~41% adjusted PAT growth in the year. We strategically expanded through in-licensing, Zuventus minority buyout and bolt-on acquisitions in the UK and Canada. Our R&D pipeline in complex injectables and biosimilars remains a key driver of future value. Our priorities remain clear – to deliver sustainable, above-industry growth and consistent margin expansion, while continuing to build sustainable long-term value for all stakeholders.”